Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/50105
Título: Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica
Autores/as: Naranjo, Antonio 
López, Rubén
García-Magallón, Blanca
Cáceres, Laura
Francisco, Félix
Jiménez-Palop, Mercedes
Ojeda-Bruno, Soledad
Clasificación UNESCO: 32 Ciencias médicas
320509 Reumatología
Palabras clave: Vertebral Fracture
Bone-Density
Double-Blind
Prevention
Risedronate, et al.
Fecha de publicación: 2014
Publicación seriada: Rheumatology International 
Resumen: The aim of this study was to analyze the longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica (PMR). Patients diagnosed with PMR were collected retrospectively in two rheumatology departments. In addition to demographic and diagnostic criteria, the chart review included the following information at baseline and at follow-up: doses of prednisone, prescription of calcium, vitamin D and bisphosphonates, bone mass measurement (BMD) and fragility fractures. We analyzed the percentage of patients undergoing BMD and were prescribed a bisphosphonate over the years. We evaluated 158 patients: 117 of them were women, mean age was 73 years, and they had an average follow-up of 4.8 years. 104 patients (66 %) received osteoporosis medication during the first visit, 44 of them were given bisphosphonate. During follow-up, another 30 treatments with bisphosphonate were added (46 % overall) while 37 cases (23 %) received no treatment with calcium or bisphosphonate. BMD was performed in 111 patients (69 %; 53 % of males and 76 % of females). Factors associated with the use of bisphosphonates were female sex (OR 4.4, 95 % CI 4.02-4.86), BMD (OR 2.4, 95 % CI 2.05-2.78) and commencement of treatment after the year 2005 (54 vs 37 %, OR 1.93, 95 % CI 1.60-2.26). No significant differences were found with age, initial doses of prednisone or the hospital. According to recent prevention guidelines, treatment with biphosphonate should have been administered in more than 90 % of patients. Although prophylaxis of glucocorticoid-induced osteoporosis in patients with PMR has increased in the recent years, many patients do not receive prophylaxis with bisphosphonate during the first visit.
URI: http://hdl.handle.net/10553/50105
ISSN: 0172-8172
DOI: 10.1007/s00296-014-3014-2
Fuente: Rheumatology International[ISSN 0172-8172],v. 34, p. 1459-1463
Colección:Artículos
Vista completa

Citas SCOPUSTM   

6
actualizado el 24-mar-2024

Citas de WEB OF SCIENCETM
Citations

5
actualizado el 25-feb-2024

Visitas

29
actualizado el 28-oct-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.